The School of Medicine and Boehringer Ingelheim Pharmaceuticals Inc. (BIPI), the Ridgefield, Conn.-based division of the German pharmaceutical firm, have formed an alliance to explore treatments for cardiovascular, inflammatory and autoimmune diseases. Under the agreement, formalized last July, BIPI will fund research projects at Yale, several of which are already under way. The projects are investigating the role of inflammation in organ rejection and atherosclerosis; channels that admit calcium into immune system cells; enzymes that act in the kidneys to regulate salt and fluid balance; and the formation of new blood vessels in the heart.
“Yale, with its excellence in immunology and cardiovascular research, offers a real opportunity for mutual benefit,” said Mikael Dolsten, M.D., Ph.D., head of corporate division pharma research at BIPI’s world headquarters in Ingelheim, Germany.
BIPI will work with scientists in the Section of Immunobiology and in the Interdepartmental Program in Vascular Biology and Transplantation.
Previous Article
New five-year public health program gives undergrads a head start
Next Article
Kessler portrait unveiled